ReviewInternational journal of molecular sciences2025
The Right Approach: Power of Biomarkers in the Assessment and Management of Right Ventricular Dysfunction.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Bleeding Events During Anticoagulation After Acute Pulmonary Embolism: Real-Life Experience.Medicina (Kaunas, Lithuania) · 2026Article
- Association of NT-proBNP With Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Intervention.JACC. Advances · 2026Article
- The Right Ventricle in Cardiac Critical Care: Pathophysiology, Evaluation and Management.Medicina (Kaunas, Lithuania) · 2026Review
- Assessment of Right Ventricular Adaptability to Pressure Overloading for Critical Therapeutic Decision-Making Processes.Journal of clinical medicine · 2026Review
- Impact of Predischarge NT-proBNP on Treatment Optimisation in Acute Heart Failure.International journal of molecular sciences · 2026Observational
- Liver Function Abnormalities in Acute Heart Failure: A State-of-the-art Review from an International Expert Group.Cardiac failure review · 2026Review
- A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.Cardiac failure review · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Right ventricular (RV) dysfunction is common and linked to poor outcomes across conditions such as heart failure (HF), acute coronary syndromes, pulmonary embolism, and pulmonary hypertension. While imaging, electrocardiogram (ECG), and invasive tests remain central to RV assessment, circulating biomarkers offer a rapid, non-invasive, and reliable alternative. These biomarkers reflect key pathophysiological processes, including myocardial injury, stress, fibrosis, inflammation, congestion, and multiorgan involvement. High-sensitivity troponins and natriuretic peptides (BNP, NT-proBNP) are already widely used, while emerging biomarkers-such as CA125, copeptin, galectin-3, and others-may enhance diagnostic accuracy and risk stratification. Some, like CA125 and NT-proBNP, have shown promise in guiding post-discharge therapy. However, challenges remain regarding the specificity of biomarkers for RV dysfunction and their role across different clinical contexts. This review provides an integrated overview of RV dysfunction, with a focus on the diagnostic and therapeutic potential of both established and novel biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.